Join us for our seminar, "Integration of Rapid Clinical Assessments and Formulation Development to Accelerate Pediatric Drug Development ".

Developing drug products for pediatric patients can present unique challenges for development teams; the broad spectrum of age ranges means that multiple product formats and/or versatile formulations may be required, and the swallowability, palatability and size of the dosage form will have a direct impact on patient compliance and hence the therapeutic benefits derived.  

Pediatric dosage forms can greatly differ from drug products designed for adult use. Development scientists must consider the route and method of administration, the safety profile, overall taste and palatability, the child’s age, weight and the treatment plan’s requirements. All these key factors must be balanced in order to develop a pediatric product that achieves clinical, regulatory and commercial success.  

In this seminar we will share strategies and case studies illustrating how key challenges in pediatric product development can be overcome, allowing drug developers to get medicines to pediatric patients in need faster.

You will learn:

• How understanding the taste of your Active Pharmaceutical Ingredient (API) early in development can help determine your taste masking strategy and target product profile (TPP) 
• How integrated clinical testing can be used to optimize pharmacokinetic (PK) performance of new pediatric drug products
• How PBPK modelling and simulation can be utilized for dose extrapolation and to predict product performance 
• How adaptive clinical manufacturing and product supply strategies can get product to global pediatric trials faster  

Register now

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Join us for our seminar, "Integration of Rapid Clinical Assessments and Formulation Development to Accelerate Pediatric Drug Development ".

Developing drug products for pediatric patients can present unique challenges for development teams; the broad spectrum of age ranges means that multiple product formats and/or versatile formulations may be required, and the swallowability, palatability and size of the dosage form will have a direct impact on patient compliance and hence the therapeutic benefits derived.  

Pediatric dosage forms can greatly differ from drug products designed for adult use. Development scientists must consider the route and method of administration, the safety profile, overall taste and palatability, the child’s age, weight and the treatment plan’s requirements. All these key factors must be balanced in order to develop a pediatric product that achieves clinical, regulatory and commercial success.  

In this seminar we will share strategies and case studies illustrating how key challenges in pediatric product development can be overcome, allowing drug developers to get medicines to pediatric patients in need faster.

You will learn:

• How understanding the taste of your Active Pharmaceutical Ingredient (API) early in development can help determine your taste masking strategy and target product profile (TPP) 
• How integrated clinical testing can be used to optimize pharmacokinetic (PK) performance of new pediatric drug products
• How PBPK modelling and simulation can be utilized for dose extrapolation and to predict product performance 
• How adaptive clinical manufacturing and product supply strategies can get product to global pediatric trials faster  

Register now

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Find out more about how the Translational Pharmaceutics® platform can be used in drug product optimization at our upcoming event.

Drug product optimization is a critical development step common for most drugs that are progressing through today’s development pipelines to respond to suboptimal exposure profiles. 

Drug product optimization is necessary to help transition from an early development formulation to one suitable for chronic administration in patients, or as part of a life-cycle management strategy. Traditional drug product optimization processes take 12-18 months to complete and place significant emphasis on the predictive power of laboratory and preclinical assessments. This approach is a non-optimal working model necessitated by the multiple disciplines required to develop, make, and test new formulations in humans.

In this presentation, Dr. Andrew Parker, Sr. Drug Development Consultant, will describe the application of Quotient Sciences’ Translational Pharmaceutics to re-engineer and streamline the drug product optimization process, using clinical data to improve decision-making and halve development timelines.

You'll learn how Translational Pharmaceutics® is applied to drug product optimization and hear case studies on reformulation programs from our expert.

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Join us for our seminar, "Integration of Rapid Clinical Assessments and Formulation Development to Accelerate Pediatric Drug Development ".

Developing drug products for pediatric patients can present unique challenges for development teams; the broad spectrum of age ranges means that multiple product formats and/or versatile formulations may be required, and the swallowability, palatability and size of the dosage form will have a direct impact on patient compliance and hence the therapeutic benefits derived.  

Pediatric dosage forms can greatly differ from drug products designed for adult use. Development scientists must consider the route and method of administration, the safety profile, overall taste and palatability, the child’s age, weight and the treatment plan’s requirements. All these key factors must be balanced in order to develop a pediatric product that achieves clinical, regulatory and commercial success.  

In this seminar we will share strategies and case studies illustrating how key challenges in pediatric product development can be overcome, allowing drug developers to get medicines to pediatric patients in need faster.

You will learn:

• How understanding the taste of your Active Pharmaceutical Ingredient (API) early in development can help determine your taste masking strategy and target product profile (TPP) 
• How integrated clinical testing can be used to optimize pharmacokinetic (PK) performance of new pediatric drug products
• How PBPK modelling and simulation can be utilized for dose extrapolation and to predict product performance 
• How adaptive clinical manufacturing and product supply strategies can get product to global pediatric trials faster  

Register now

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.